RIMAG GROUP (02522) has issued an announcement regarding the completion of its acquisition transactions. On April 26, 2026, the company, its buyer subsidiary RIMAG Medical Imaging (Hong Kong) Co., Limited, seller 1 Sun Seeds Management Co., Limited, and target company 1 Hong Kong Sun Seeds Management Co., Limited entered into a share purchase agreement 1. Under this agreement, the buyer intended to purchase target equity 1, representing 100% of the shares of target company 1, for a total consideration of HKD 185 million.
Additionally, the company, the buyer, seller 2 Yong'an Value No. 4 Limited Partnership Fund, and target company 2 Wingon Medical Technology Co., Limited (Yongan Medical Technology Co., Limited) entered into share purchase agreement 2. This agreement stipulated that the buyer would purchase target equity 2, representing 100% of the shares of target company 2, for a total consideration of HKD 168 million. The consideration was to be settled through the company issuing consideration shares to the sellers.
All conditions precedent for the acquisitions were met on August 27, 2026. In accordance with the share purchase agreements, the company transferred 5,736,500 treasury shares and allotted and issued 23,206,000 new H-shares to seller 1, while also allotting and issuing 26,229,500 new H-shares to seller 2 as payment of the consideration. Consequently, the acquisitions have been officially completed.
As of the date of this announcement, the total issued share capital of the company has increased to 450 million shares, comprising 107 million unlisted shares and 344 million H-shares. The company currently holds no treasury shares.
Comments